Bionano Genomics Announces Issuance of a U.S. Patent for Analysis of Small Nucleic Acid Fragments in Nanochannel Arrays
June 29 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that
the United States Patent and Trademark Office issued US
Patent No.11,359,244 on June 14, 2022. The patent, titled
“CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS” claims methods for
the analysis of small nucleic acid fragments in nanochannel arrays,
which Bionano has traditionally used to analyze ultra-high
molecular weight (UHMW) DNA for the identification of structural
variants (SVs) as part of its Saphyr® system. The methods claim the
use of certain nanochannel arrays to detect and quantitate genetic
abnormalities, including a DNA translocation, amplification,
transversion, inversion, aneuploidy, polyploidy, monosomy, trisomy,
trisomy 21, trisomy 13, trisomy 14, trisomy 15, trisomy 16, trisomy
18, trisomy 22, triploidy, tetraploidy, and sex chromosome
aneuploidy.
Nanochannel arrays have the potential to enable single molecule
assays for circulating DNA found in blood and other fluid samples,
which tend to be highly fragmented with average lengths between 150
– 200 base pairs. Bionano believes that the methods disclosed in
the ‘244 patent may one day support the commercialization of assays
directed to non-invasive prenatal testing (NIPT) in maternal fetal
medicine or ctDNA in oncology.
The patent is part of Bionano’s intellectual property portfolio
that includes multiple patents covering its core technology of
confining and linearizing ultra-long DNA and other macromolecules
in parallel nanochannel arrays, and the detection of
feature-specific sequence or genomic labels on those molecules.
Additionally, Bionano’s portfolio includes patents directed to
methods of fabricating nanochannel devices, as well as other
technologies for sample processing and analysis related
workflows.
“At Bionano, we remain committed to expanding the utility of our
nanochannel arrays and creating a robust patent portfolio that
protects those applications. This patent is an exciting example of
technology that may prove useful for creating new applications in
important areas of medicine,” commented Erik Holmlin, PhD,
president and chief executive officer of Bionano Genomics.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “potential,” “believe,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the anticipated benefits and improvements resulting from the
methods described in this patent, and the ability of the tools that
we may develop to provide new insight into circulating nucleic
acids for applications directed to NIPT in maternal fetal medicine
or ctDNA in oncology. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape and the introduction of competitive technologies or
improvements in existing technologies; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission,
including, without limitation, our Annual Report on Form 10-K for
the year ended December 31, 2021 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024